Novogen boss resigns
PHARMA CEUTICALS company Novogen has lost a pioneer in anticancer drugs with the sudden resignation of its chief executive and founder Dr Graham Kelly.
Dr Kelly will resume his work in non- oncology- based research after resigning yesterday, effective immediately, causing the company’s share price to drop 2c, or 8.51 per cent, to 21.5c at 1401 AEST.
“I am satisfied I am leaving the company in a very sound position,” Dr Kelly said in a statement.
“The company is well placed now to proceed into the clinic with its three oncology drug candidates.
“My particular interest and skills are in early- stage drug development and I now want to focus on that.”
Dr Kelly, a prostate cancer sufferer himself who has expressed a desire see anti- cancer drugs provided to families at an affordable price, left the company in 2005 after founding it in 1994, and rejoined in 2012.